Tyrosine kinases as targets for cancer therapy

被引：1051

作者：

Krause, DS

Van Etten, RA

机构：

[1] Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA

[2] Tufts Univ, New England Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02111 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 353卷 / 02期

关键词：

D O I：

10.1056/NEJMra044389

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：172 / 187

页数：16

共 123 条

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].

Agus, DB ;

Akita, RW ;

Fox, WD ;

Lewis, GD ;

Higgins, B ;

Pisacane, PI ;

Lofgren, JA ;

Tindell, C ;

Evans, DP ;

Maiese, K ;

Scher, HI ;

Sliwkowski, MX .

CANCER CELL, 2002, 2 (02) :127-137

[2] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[3] Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? [J].

Arteaga, CL ;

Baselga, J .

CANCER CELL, 2004, 5 (06) :525-531

[4] Amplification of the ABL gene in T-cell acute lymphoblastic leukemia [J].

Barber, KE ;

Martineau, M ;

Harewood, L ;

Stewart, M ;

Cameron, E ;

Strefford, JC ;

Rutherford, S ;

Allen, TD ;

Broadfield, ZJ ;

Cheung, KL ;

Harris, RL ;

Jalali, GR ;

Moorman, AV ;

Robinson, HM ;

Harrison, CJ .

LEUKEMIA, 2004, 18 (06) :1153-1156

[5] Mutational analysis of the tyrosine kinome in colorectal cancers [J].

Bardelli, A ;

Parsons, DW ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Saha, S ;

Markowitz, S ;

Willson, JKV ;

Parmigiani, G ;

Kinzler, KW ;

Vogelstein, B ;

Velculescu, VE .

SCIENCE, 2003, 300 (5621) :949-949

[6] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[7] The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA [J].

Baxter, EJ ;

Hochhaus, A ;

Bolufer, P ;

Reiter, A ;

Fernandez, JM ;

Senent, L ;

Cervera, J ;

Moscardo, F ;

Sanz, MA ;

Cross, NCP .

HUMAN MOLECULAR GENETICS, 2002, 11 (12) :1391-1397

[8] Expression and mutational status of c-kit in small-cell lung cancer:: Prognostic relevance [J].

Boldrini, L ;

Ursino, S ;

Gisfredi, S ;

Faviana, P ;

Donati, V ;

Camacci, T ;

Lucchi, M ;

Mussi, A ;

Basolo, F ;

Pingitore, R ;

Fontanini, G .

CLINICAL CANCER RESEARCH, 2004, 10 (12) :4101-4108

[9] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[10] Imatinib mesylate in chordoma [J].

Casali, PG ;

Messina, A ;

Stacchiotti, S ;

Tamborini, E ;

Crippa, F ;

Gronchi, A ;

Orlandi, R ;

Ripamonti, C ;

Spreafico, C ;

Bertieri, R ;

Bertulli, R ;

Colecchia, M ;

Fumagalli, E ;

Greco, A ;

Grosso, F ;

Olmi, P ;

Pierotti, MA ;

Pilotti, S .

CANCER, 2004, 101 (09) :2086-2097

← 1 2 3 4 5 6 7 8 9 10 →